Supernus Pharmaceuticals (SUPN) Non-Current Deffered Revenue (2011 - 2017)

Supernus Pharmaceuticals (SUPN) has 7 years of Non-Current Deffered Revenue data on file, last reported at $1.1 million in Q4 2017.

• On a quarterly basis, Non-Current Deffered Revenue fell 23.45% year-over-year to $1.1 million in Q4 2017; TTM through Dec 2017 was $1.1 million, a 23.45% decrease from a year earlier, with the FY2017 full-year figure at $1.1 million, down 23.45% from the prior year.
• Non-Current Deffered Revenue for Q4 2017 stood at $1.1 million, down from $1.2 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for SUPN reached as high as $1.7 million in Q1 2016 and fell as low as $738000.0 in Q2 2013.
• Historically, Non-Current Deffered Revenue has averaged $1.3 million across 5 years, with a median of $1.3 million in 2014.
• Across the five-year window, Non-Current Deffered Revenue surged 358.58% in 2013 and declined 23.45% in 2017, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $1.4 million in 2013, then slipped by 10.09% to $1.3 million in 2014, then grew by 9.11% to $1.4 million in 2015, then gained by 7.99% to $1.5 million in 2016, then dropped by 23.45% to $1.1 million in 2017.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $1.1 million in Q4 2017, $1.2 million in Q3 2017, and $1.3 million in Q2 2017.